主页 > 医学前沿 >
【drug-news】血管瘤伴血小板减少综合征：干扰素
http://highwire.stanford.edu/cgi/medline/pmid;16000250?maxtoshow=&HITS=&hits=&RESULTFORMAT=&fulltext=Kasabach-Merritt&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&fdate=1/1/2006&resourcetype=HWCIT
原文标题
Kasabach-Merritt syndrome: dangers of interferon and successful treatment with pentoxifylline
摘要
A girl aged 3 months presented with thrombocytopenia and bruising around a large vascular malformation of her posterior abdominal wall. Treatment was started with corticosteroids and platelet replacement, but with no improvement and a platelet count persistently less than 10 x 10(9)/L over 3 weeks, alpha-interferon was added. There was an immediate increase in bruising, a fall in platelet count, and an increase in platelet transfusion requirement until interferon was discontinued 11 days later. After a further week, the platelet count returned to the levels before interferon, but the patient did not develop any further symptoms. The platelet count remained low with no clinical change until pentoxifylline was started at the age of 15 months. The platelet count rose to 117 x 10(9)/L within 4 days and remained more than 100 x 10(9)/L thereafter. The patient is now 7 years old and has had no recurrence since stopping the pentoxifylline at the age of 5 years. Although thrombocytopenia is a recognized side effect of interferon therapy, this very dangerous complication has not been previously reported using interferon for the Kasabach-Merritt syndrome. Kasabach-Merritt syndrome: dangers of interferon and successful treatment with pentoxifylline
血管瘤伴血小板减少综合征：干扰素的危害与循能泰的成功治疗
A girl aged 3 months presented with thrombocytopenia and bruising around a large vascular malformation of her posterior abdominal wall.
一个3个月大的女婴被发现有血小板减少症，而且在她腹后壁有一个大的畸形血管，周围青紫。
Treatment was started with corticosteroids and platelet replacement, but with no improvement and a platelet count persistently less than 10 x 10(9)/L over 3 weeks, alpha-interferon was added.
治疗首先采用了皮质激素和血小板替代物，但病情没有得到改善，而且血小板计数持续3周多都低于10 x 10(9)/L，于是加用了α-干扰素。
There was an immediate increase in bruising, a fall in platelet count, and an increase in platelet transfusion requirement until interferon was discontinued 11 days later.
随后立即出现了青紫加重、血小板计数下降、血小板输注需求增加等情况，直到11天后停用干扰素。
After a further week, the platelet count returned to the levels before interferon, but the patient did not develop any further symptoms.
一周后，血小板计数恢复到使用干扰素前的水平，但患者没有再出现任何加重的症状。
The platelet count remained low with no clinical change until pentoxifylline was started at the age of 15 months.
血小板计数持续偏低，没有任何临床改变，直到在患者15个月大时开始接受循能泰治疗。
The platelet count rose to 117 x 10(9)/L within 4 days and remained more than 100 x 10(9)/L thereafter.
血小板计数4天内便升至117 x 10(9)/L，且之后持续高于100 x 10(9)/L。
The patient is now 7 years old and has had no recurrence since stopping the pentoxifylline at the age of 5 years.
患者如今7岁，在5岁停用循能泰之后至今疾病没有复发。
Although thrombocytopenia is a recognized side effect of interferon therapy, this very dangerous complication has not been previously reported using interferon for the Kasabach-Merritt syndrome.
尽管人们对于干扰素治疗有血小板减少的副作用是有所认识的，但此前并没有报道过，在对血管瘤伴血小板减少综合征进行的干扰素治疗中会发生这种非常危险的并发症。 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-23 17:11
医学,生命科学网